October 2014

New Product - Adcetris

Adcetris (brentuximab vedotin) is an antibody drug conjugate (ADC) that delivers an antineoplastic agent that results in apoptotic cell death in CD30 expressing tumour cells (such as classical Hodgkin's lymphoma and systemic anaplastic large cell lymphoma). Adcetris is indicated in the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. It is also indicated in the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Combined use of bleomycin and Adcetris is contraindicated as it causes pulmonary toxicity. Adcetris (50 mg) is available as a powder for infusion in packs of 1's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au